Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40)
- 1 August 2015
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (16) , 3105-3111
Abstract
No abstract availableKeywords
Funding Information
- Russian Scientific Fund (14-50-00069)
This publication has 33 references indexed in Scilit:
- Treatment of Type 2 Diabetes by Free Fatty Acid Receptor AgonistsFrontiers in Endocrinology, 2014
- Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitusBioorganic & Medicinal Chemistry Letters, 2014
- Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesityBioorganic & Medicinal Chemistry Letters, 2013
- Glucose‐stimulated insulin secretion: A newer perspectiveJournal of Diabetes Investigation, 2013
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trialsDiabetes & Metabolism, 2012
- Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 AgonistACS Medicinal Chemistry Letters, 2010
- β-Cell Failure in Diabetes and Preservation by Clinical TreatmentEndocrine Reviews, 2007
- Sulfonylurea Induced β-Cell Apoptosis in Cultured Human IsletsThe Journal of Clinical Endocrinology & Metabolism, 2005
- Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40Nature, 2003
- Sulphonylurea‐induced hypoglycaemia in type 2 diabetes mellitus: a reviewDiabetes, Obesity and Metabolism, 1999